Top Low Price Stocks To Invest In Right Now

What happened

Shares of Rogers Corp. (NYSE:ROG) gained 19.9% in April 2017, according to data from S&P Global Market Intelligence.

So what

The company reported first-quarter results on April 26, sending share prices nearly 12% higher the next day. Rogers saw 27% year-over-year sales growth and 79% higher earnings, leaving analyst estimates far behind in both cases.

A Rogers engineer, hard at work on next-generation battery materials. Image source: Rogers.

Now what

Rogers shares have now gained 72% over the last 52 weeks, trading steadily near all-time highs. The maker of specialized materials used in battery systems and wireless antennas has consistently delivered solid earnings surprises over the last three years, often coupled with equally strong revenue wins.

This company is poised to continue making a killing in several emerging markets, including the Internet of Things and automotive computing. Best of all, Rogers is winning competitive contracts without resorting to pricing discounts. Trailing operating margins have increased from 12.4% to 14.2% over the last four quarters. In other words, clients are choosing Rogers over rival materials providers for other reasons than low prices, such as product quality and dependable ordering and delivery processes.

Top Low Price Stocks To Invest In Right Now: RetailMeNot, Inc.(SALE)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of RetailMeNot Inc (NASDAQ: SALE) got a boost, shooting up 12 percent to $8.42. RetailMeNot announced after Thursday’s close it has entered into an agreement to acquire GiftCard Zen, a secondary marketplace for gift cards. The company reported preliminary Q1 revenue of $54 million to $54.5 million and FY16 revenue of $228 million to $241 million.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, RetailMeNot (NASDAQ:SALE) and SUPERVALU (NYSE:SVU) attracted heavy investor interest following merger and acquisition news.

Top Low Price Stocks To Invest In Right Now: Astrotech Corporation(ASTC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Astrotech Corp (NASDAQ: ASTC) shares shot up 70 percent to $4.83. Astrotech reported that it has completed its successful 1st Detect demo with Department of Homeland Security and Transportation Security Administration personnel.

  • [By Lisa Levin]

    Astrotech Corp (NASDAQ: ASTC) shares shot up 60 percent to $4.37. Astrotech reported that it has completed its successful 1st Detect demo with Department of Homeland Security and Transportation Security Administration personnel.

Top Low Price Stocks To Invest In Right Now: Regeneron Pharmaceuticals, Inc.(REGN)

Advisors’ Opinion:

  • [By Ben Levisohn]

    Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.

    Getty Images

    Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.

    RBC’s Adnan Butt and Michael Yee offer their take:

    Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…

    Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.

    Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.

  • [By WWW.THESTREET.COM]

    That’s why Cramer said he’ll be listening for news coming from Celgene (CEL) , Amgen (AMGN) , Allergan (AGN) , an Action Alerts PLUS holding, and Regenron (REGN) , all of which are set to present. Of the four, Cramer said he’s sticking with Allergan and Amgen.

  • [By Ben Levisohn]

    After years of rising and falling in tandem, the biotech sector is all about stock picking now. Credit Suisse analyst Alethia Young and team, for instance, upgraded Regeneron Pharmaceuticals (REGN), and added Celgene (CELG) to its Focus List today. But Amgen (AMGN) wasn’t so lucky as Young cut it to Neutral from Outperform. She explains why:

Top Low Price Stocks To Invest In Right Now: Federated Investors, Inc.(FII)

Advisors’ Opinion:

  • [By Gregg Greenberg]

     Stocks of Federated Investors (FII) fell approximately 9% in 2015, yet Oja expects a big turnaround in 2016, once again due to the prospect of higher rates ahead. 

     

    "The money market fund business, which is unprofitable now, should become more profitable as rates rise because Federated has to reimburse for the servicing fees for these funds," said Oja, who also admires the fund company’s 3.5% dividend yield. 

     

    Oja added that Federated also has a "good core business of equity and fixed-income asset management." 

Leave a Reply

Your email address will not be published. Required fields are marked *